Search for content, post, videos

Cytovation completes financing round of 30 million NOK

Cytovation has raised NOK 10m in a private funding round, completing the second stage of fundraising, having raised NOK 20m in June 2017.

Both financings were led by a group of private investors in Norway and the company will now use these funds to advance lead product CyPep-H1 through the final stages of pre-clinical development and into and through a Phase I/IIa clinical trial in patients with warts caused by the human papilloma virus (HPV).

“The completion of this final tranche of fundraising now enables Cytovation to move through toxicology studies and formulation and into our planned Phase I/IIa clinical trial for CyPep-H1. We expect initial results from this study late 2018 and are confident that they will confirm the potential of this novel treatment approach for the many largely unsatisfied patients globally, who suffer from cutaneous warts,” said Cytovation’s CEO, Kjell Inge Arnevig.

Source: Cytovation